Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs

Martínez-Domínguez, Samuel J. (Universidad de Zaragoza) ; García-Mateo, Sandra (Universidad de Zaragoza) ; Sainz-Arnal, Pilar ; Martínez-García, Javier ; Gallego-Llera, Beatriz ; Lozano-Limones, María Jesús ; Hidalgo, Sandra ; Gargallo-Puyuelo, Carla J. (Universidad de Zaragoza) ; Latre-Santos, Marta ; Nocito-Colon, Maria Mercedes Lourdes ; Martínez-Lostao, Luis (Universidad de Zaragoza) ; Refaie, Engy ; Arroyo-Villarino, Maria Teresa (Universidad de Zaragoza) ; del Rio-Nechaevsky, Marcela ; Ramirez-Labrada, Ariel ; Pardo, Julián ; Gomollón, Fernando (Universidad de Zaragoza) ; Baptista, Pedro M.

Resumen: Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy.

Idioma: Inglés

DOI: 10.1038/s41598-023-50537-y

Año: 2023

Publicado en: Scientific reports (Nature Publishing Group) 13, 1 (2023), 23061 [11 pp.]
ISSN: 2045-2322

Factor impacto JCR: 3.8 (2023)

Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 25 / 134 = 0.187 (2023) - Q1 - T1

Factor impacto CITESCORE: 7.5 - Multidisciplinary (Q1)

Factor impacto SCIMAGO: 0.9 - Multidisciplinary (Q1)

Financiación: info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00
Financiación: info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-100087

Tipo y forma: Article (Published version)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Inmunología (Dpto. Microb.Ped.Radio.Sal.Pú.)